Loading data…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$40.07M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| January 1, 2025 – December 31, 2025 | $258,897,000 | April 24, 2026 | 20-F ↗ |
| January 1, 2024 – December 31, 2024 | $182,603,000 | April 24, 2026 | 20-F ↗ |
| January 1, 2023 – December 31, 2023 | $352,860,000 | April 24, 2026 | 20-F ↗ |
| January 1, 2022 – December 31, 2022 | $613,641,000 | April 25, 2025 | 20-F ↗ |
| January 1, 2021 – December 31, 2021 | $980,778,000 | April 28, 2022 | 20-F ↗ |
| January 1, 2020 – December 31, 2020 | $985,956,000 | April 19, 2021 | 20-F ↗ |
| January 1, 2019 – December 31, 2019 | $834,878,000 | April 23, 2020 | 20-F ↗ |
| January 1, 2018 – December 31, 2018 | $530,192,000 | April 12, 2019 | 20-F ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 13, 2026
Response SHA-256: 821fe41349f3a0250bbb5510ac672d485fb51fb32afc3eb77f3a9cb7771a6fcb
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.